1. Home
  2. COR vs ARGX Comparison

COR vs ARGX Comparison

Compare COR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cencora Inc.

COR

Cencora Inc.

HOLD

Current Price

$306.31

Market Cap

59.1B

Sector

Health Care

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$958.64

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COR
ARGX
Founded
2001
2008
Country
United States
Netherlands
Employees
51000
N/A
Industry
Other Pharmaceuticals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.1B
58.4B
IPO Year
2001
2017

Fundamental Metrics

Financial Performance
Metric
COR
ARGX
Price
$306.31
$958.64
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
$390.62
★ $1,008.56
AVG Volume (30 Days)
★ 1.0M
204.3K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
★ 0.77%
N/A
EPS Growth
★ 5.71
N/A
EPS
★ 15.21
N/A
Revenue
★ $321,332,819,000.00
N/A
Revenue This Year
$8.89
$44.39
Revenue Next Year
$6.75
$20.84
P/E Ratio
★ $20.37
$33.69
Revenue Growth
★ 9.31
N/A
52 Week Low
$244.82
$661.85
52 Week High
$377.54
$1,072.75

Technical Indicators

Market Signals
Indicator
COR
ARGX
Relative Strength Index (RSI) 39.07 44.84
Support Level $299.49 $836.30
Resistance Level $312.18 $1,072.75
Average True Range (ATR) 7.24 19.61
MACD -2.14 -9.56
Stochastic Oscillator 9.50 31.66

Price Performance

Historical Comparison
COR
ARGX

About COR Cencora Inc.

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: